Evaluation of the Safety and Immunogenicity of the RTS,S/AS01_E Malaria Candidate Vaccine When Integrated in the Expanded Program of ImmunizationAGNANDJI, Selidji T; ASANTE, Kwaku Poku; CHIKAWE, Maria et al.The Journal of infectious diseases. 2010, Vol 202, Num 7, pp 1076-1087, issn 0022-1899, 12 p.Article

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trialOLOTU, Ally; LUSINGU, John; VANSADIA, Preeti et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 2, pp 102-109, issn 1473-3099, 8 p.Article

Safety and efficacy of the RTS,S/AS01_E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trialKWAKU POKU ASANTE; ABDULLA, Salim; SALIM, Nahya et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 10, pp 741-749, issn 1473-3099, 9 p.Article

Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult SubjectsBROTHERS, Cindy H; HERNANDEZ, Jaime E; CUTRELL, Amy G et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 1, pp 20-28, issn 1525-4135, 9 p.Article